---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-103026"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:38:04.078032+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx Q2 revenue $166M (+13% YoY); net loss narrows; UX111 BLA receives CRL

## Summary
- Q2 total revenue $166M, Crysvita $120M, Dojolvi $23M; net loss $115M ($1.17/sh) vs $132M loss prior year.
- Reaffirms 2025 guidance: total rev $640-670M, Crysvita $460-480M, Dojolvi $90-100M; path to profitability in 2027.
- UX111 gene therapy for Sanfilippo type A received FDA CRL for CMC/manufacturing issues; clinical data package no issues; resubmission after Type A meeting.
- GTX-102 for Angelman syndrome granted Breakthrough Therapy; Phase 3 Aspire fully enrolled (129 pts); data expected H2 2026.
- UX143 Phase 3 final analysis expected end of 2025; DTX401 BLA submission planned Q4 2025; cash $539M as of June 30.

## SEC filing metadata
- accession: 0000950170-25-103026
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017025103026/0000950170-25-103026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017025103026/rare-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-103026
- JSON: https://secwatch.observer/filing/0000950170-25-103026.json
- Plain text: https://secwatch.observer/filing/0000950170-25-103026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.